{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:13:15Z","timestamp":1768464795667,"version":"3.49.0"},"reference-count":167,"publisher":"Portland Press Ltd.","issue":"11","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:p>Cancers have traditionally been classified based on their tissue of origin. However, with advances in sophisticated genome sequencing techniques and progression toward an era of precision medicine, it has become increasingly clear that classifying tumors based on unifying molecular features instead of tissue of origin may hold the key to improving patient outcomes. Various efforts have been undertaken to address this critical aspect of cancer biology, but it is still unclear as to the best approach to stratify tumors into different molecular classes. One approach is to define many small subclasses based on complex molecular signatures, while another option is to divide cancers into larger groups based on higher-order features of cancer behavior. This latter approach holds appeal as it may provide opportunities to identify broadly relevant therapeutics. However, our understanding of these fundamental \u2018rules\u2019 of cancer biology and how they can be used to better classify and treat cancers is in its infancy. We recently demonstrated that cancers can be functionally stratified into binary YAPon and YAPoff super-classes with unique therapeutic vulnerabilities based on distinct expression and function of the transcriptional coactivators, YAP and TAZ. In YAPon cancers, YAP and TAZ drive oncogenesis, whereas in YAPoff cancers, YAP and TAZ are instead tumor suppressors. In this review, we discuss our understanding of these distinct cancer classes with a focus on the mechanisms that underlie the opposite function of YAP\/TAZ in YAPon and YAPoff cancers, as well as the potential therapeutic implications of these findings.<\/jats:p>","DOI":"10.1042\/bcj20253077","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:21:38Z","timestamp":1749046898000},"page":"741-761","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular basis and therapeutic implications of binary YAPOn\/YAPOff cancer classes"],"prefix":"10.1042","volume":"482","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0260-1419","authenticated-orcid":false,"given":"Pinky","family":"Sharma","sequence":"first","affiliation":[{"name":"1Department of Pharmacology & Therapeutics, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada"},{"name":"2Paul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-5922","authenticated-orcid":false,"given":"Yale S.","family":"Michaels","sequence":"additional","affiliation":[{"name":"2Paul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, MB, Canada"},{"name":"3Department of Biochemistry & Medical Genetics, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7559-4897","authenticated-orcid":false,"given":"Joel D.","family":"Pearson","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology & Therapeutics, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada"},{"name":"2Paul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, MB, Canada"},{"name":"4Children\u2019s Hospital Research Institute of Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"2025060410212998600_BCJ-2025-3077C1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"2025060410212998600_BCJ-2025-3077C2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"2025060410212998600_BCJ-2025-3077C3","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1158\/1078-0432.CCR-17-3378","article-title":"Pan-cancer molecular classes transcending tumor lineage across 32 cancer types, multiple data platforms, and over 10,000 cases","volume":"24","author":"Chen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13528-0","article-title":"Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers","volume":"10","author":"Chen","year":"2019","journal-title":"Nat. Commun."},{"key":"2025060410212998600_BCJ-2025-3077C5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"2025060410212998600_BCJ-2025-3077C6","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ccell.2023.06.009","article-title":"Proteogenomic data and resources for pan-cancer analysis","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMp1607591","article-title":"Toward a shared vision for cancer genomic data","volume":"375","author":"Grossman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2025060410212998600_BCJ-2025-3077C8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","article-title":"Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin","volume":"158","author":"Hoadley","year":"2014","journal-title":"Cell"},{"key":"2025060410212998600_BCJ-2025-3077C9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.celrep.2018.03.077","article-title":"Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers","volume":"23","author":"Peng","year":"2018","journal-title":"Cell Rep."},{"key":"2025060410212998600_BCJ-2025-3077C10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"2025060410212998600_BCJ-2025-3077C11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ccell.2024.12.002","article-title":"Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets","volume":"43","author":"Ellrott","year":"2025","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C12","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"2025060410212998600_BCJ-2025-3077C13","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11070612","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"11","author":"Wagener-Ryczek","year":"2021","journal-title":"J. Pers. Med."},{"key":"2025060410212998600_BCJ-2025-3077C14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ccell.2021.06.016","article-title":"Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP\/TEAD activity","volume":"39","author":"Pearson","year":"2021","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C15","article-title":"Simplifying cancer: binary pan-cancer superclasses stratified by opposite YAP\/TEAD effects","volume":"8","author":"Pearson","year":"2021","journal-title":"Mol. Cell. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41568-023-00579-1","article-title":"Insights into recent findings and clinical application of YAP and TAZ in cancer","volume":"23","author":"Franklin","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"2025060410212998600_BCJ-2025-3077C17","first-page":"9","article-title":"YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches","volume":"4","author":"Piccolo","year":"2023","journal-title":"Nat. Cancer"},{"key":"2025060410212998600_BCJ-2025-3077C18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","article-title":"YAP\/TAZ at the roots of cancer","volume":"29","author":"Zanconato","year":"2016","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C19","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1158\/0008-5472.CAN-11-1020","article-title":"miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer","volume":"71","author":"Nishikawa","year":"2011","journal-title":"Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C20","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg1850","article-title":"YAP drives fate conversion and chemoresistance of small cell lung cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Sci. Adv."},{"key":"2025060410212998600_BCJ-2025-3077C21","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1158\/2767-9764.CRC-24-0101","article-title":"Netrin-1 and UNC5B cooperate with integrins to mediate YAP-driven cytostasis","volume":"4","author":"Pearson","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"2025060410212998600_BCJ-2025-3077C22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.21037\/cco-23-97","article-title":"Expression of YAP suppresses cell proliferation and elevates the sensitivity of chemotherapy in retinoblastoma cells through lipid-peroxidation induced ferroptosis","volume":"12","author":"Zhong","year":"2023","journal-title":"Chin. Clin. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C23","article-title":"A miR-375\/YAP axis regulates neuroendocrine differentiation and tumorigenesis in lung carcinoid cells","volume":"11","author":"Yang","year":"2021","journal-title":"Sci. Rep."},{"key":"2025060410212998600_BCJ-2025-3077C24","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157171","article-title":"YAP1 and WWTR1 expression inversely correlates with neuroendocrine markers in merkel cell carcinoma","volume":"133","author":"Frost","year":"2023","journal-title":"J. Clin. Invest."},{"key":"2025060410212998600_BCJ-2025-3077C25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5483\/BMBRep.2018.51.3.015","article-title":"DNA binding partners of YAP\/TAZ","volume":"51","author":"Kim","year":"2018","journal-title":"BMB Rep."},{"key":"2025060410212998600_BCJ-2025-3077C26","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1101\/gad.1664408","article-title":"TEAD mediates YAP-dependent gene induction and growth control","volume":"22","author":"Zhao","year":"2008","journal-title":"Genes Dev."},{"key":"2025060410212998600_BCJ-2025-3077C27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005465","article-title":"YAP1 exerts its transcriptional control via TEAD-mediated activation of enhancers","volume":"11","author":"Stein","year":"2015","journal-title":"Plos Genet"},{"key":"2025060410212998600_BCJ-2025-3077C28","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1242\/dev.027151","article-title":"Mammalian tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of hippo signaling","volume":"135","author":"Ota","year":"2008","journal-title":"Development"},{"key":"2025060410212998600_BCJ-2025-3077C29","doi-asserted-by":"crossref","first-page":"E2441","DOI":"10.1073\/pnas.1212021109","article-title":"The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain","volume":"109","author":"Lamar","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2025060410212998600_BCJ-2025-3077C30","article-title":"YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis","volume":"14","author":"Wu","year":"2023","journal-title":"Nat. Commun."},{"key":"2025060410212998600_BCJ-2025-3077C31","article-title":"Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1","volume":"13","author":"Chen","year":"2022","journal-title":"Nat. Commun."},{"key":"2025060410212998600_BCJ-2025-3077C32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ccr.2011.04.019","article-title":"Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung","volume":"19","author":"Sutherland","year":"2011","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30416-2","article-title":"A conserved YAP\/Notch\/REST network controls the neuroendocrine cell fate in the lungs","volume":"13","author":"Shue","year":"2022","journal-title":"Nat. Commun."},{"key":"2025060410212998600_BCJ-2025-3077C34","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1016\/j.celrep.2020.02.052","article-title":"FGFR1 oncogenic activation reveals an alternative cell of origin of SCLC in Rb1\/p53 mice","volume":"30","author":"Ferone","year":"2020","journal-title":"Cell Rep."},{"key":"2025060410212998600_BCJ-2025-3077C35","doi-asserted-by":"crossref","first-page":"22300","DOI":"10.1073\/pnas.1821745116","article-title":"Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes","volume":"116","author":"L\u00e1zaro","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2025060410212998600_BCJ-2025-3077C36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nm.3562","article-title":"Rescue of hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers","volume":"20","author":"Cottini","year":"2014","journal-title":"Nat. Med."},{"key":"2025060410212998600_BCJ-2025-3077C37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1158\/1541-7786.MCR-17-0382","article-title":"Novel YAP1 activator, identified by transcription-based functional Ssreen, limits multiple myeloma growth","volume":"16","author":"Maruyama","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C38","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1182\/bloodadvances.2019000374","article-title":"TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC","volume":"3","author":"Grieve","year":"2019","journal-title":"Blood Adv."},{"key":"2025060410212998600_BCJ-2025-3077C39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.exphem.2023.04.004","article-title":"MST1 downregulates TAZ tumor suppressor protein in multiple myeloma and is a potential therapeutic target","volume":"123","author":"Abegunde","year":"2023","journal-title":"Exp. Hematol."},{"key":"2025060410212998600_BCJ-2025-3077C40","article-title":"TAZ upregulates MIR-224 to inhibit oxidative stress response in multiple myeloma","volume":"6","author":"Abegunde","year":"2023","journal-title":"Cancer Rep. (Hoboken)"},{"key":"2025060410212998600_BCJ-2025-3077C41","first-page":"877","article-title":"Che-1\/miR-590-3p\/TAZ axis sustains multiple myeloma disease","volume":"38","author":"Bruno","year":"2024","journal-title":"Leukemia, Nature Publishing Group"},{"key":"2025060410212998600_BCJ-2025-3077C42","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41375-018-0111-3","article-title":"YAP and TAZ are dispensable for physiological and malignant haematopoiesis","volume":"32","author":"Donato","year":"2018","journal-title":"Leukemia"},{"key":"2025060410212998600_BCJ-2025-3077C43","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/cas.13078","article-title":"YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer","volume":"107","author":"Horie","year":"2016","journal-title":"Cancer Sci."},{"key":"2025060410212998600_BCJ-2025-3077C44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/path.5781","article-title":"Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer","volume":"255","author":"Asrani","year":"2021","journal-title":"J. Pathol."},{"key":"2025060410212998600_BCJ-2025-3077C45","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1007\/s00018-021-03781-2","article-title":"Context-dependent roles of YAP\/TAZ in stem cell fates and cancer","volume":"78","author":"LeBlanc","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"2025060410212998600_BCJ-2025-3077C46","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/ncb3216","article-title":"Genome-wide association between YAP\/TAZ\/TEAD and AP-1 at enhancers drives oncogenic growth","volume":"17","author":"Zanconato","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"2025060410212998600_BCJ-2025-3077C47","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.celrep.2015.12.104","article-title":"Tead and AP1 coordinate transcription and motility","volume":"14","author":"Liu","year":"2016","journal-title":"Cell Rep."},{"key":"2025060410212998600_BCJ-2025-3077C48","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.celrep.2019.05.071","article-title":"The Myb-MuvB complex is required for YAP-dependent transcription of mitotic genes","volume":"27","author":"Pattschull","year":"2019","journal-title":"Cell Rep."},{"key":"2025060410212998600_BCJ-2025-3077C49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.molcel.2007.12.022","article-title":"Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage","volume":"29","author":"Levy","year":"2008","journal-title":"Mol. Cell"},{"key":"2025060410212998600_BCJ-2025-3077C50","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/cdd.2014.182","article-title":"c-Abl antagonizes the YAP oncogenic function","volume":"22","author":"Keshet","year":"2015","journal-title":"Cell Death Differ."},{"key":"2025060410212998600_BCJ-2025-3077C51","doi-asserted-by":"crossref","first-page":"27534","DOI":"10.1074\/jbc.M804380200","article-title":"Mst2 and lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP)","volume":"283","author":"Oka","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2025060410212998600_BCJ-2025-3077C52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045498","article-title":"Alteration of TEAD1 expression levels confers apoptotic resistance through the transcriptional up-regulation of livin","volume":"7","author":"Landin Malt","year":"2012","journal-title":"Plos One"},{"key":"2025060410212998600_BCJ-2025-3077C53","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat. Commun."},{"key":"2025060410212998600_BCJ-2025-3077C54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"key":"2025060410212998600_BCJ-2025-3077C55","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/2159-8290.CD-20-1863","article-title":"Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation","volume":"11","author":"Quintanal-Villalonga","year":"2021","journal-title":"Cancer Discov."},{"key":"2025060410212998600_BCJ-2025-3077C56","doi-asserted-by":"crossref","DOI":"10.1126\/science.adj1415","article-title":"Lineage-specific intolerance to oncogenic drivers restricts histological transformation","volume":"383","author":"Gardner","year":"2024","journal-title":"Science"},{"key":"2025060410212998600_BCJ-2025-3077C57","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54480-y","article-title":"Functional annotation of the hippo pathway somatic mutations in human cancers","volume":"15","author":"Han","year":"2024","journal-title":"Nat. Commun."},{"key":"2025060410212998600_BCJ-2025-3077C58","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1878-0261.13124","article-title":"Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state","volume":"16","author":"Yan","year":"2022","journal-title":"Mol. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C59","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167440","article-title":"LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function","volume":"8","author":"Kumaraswamy","year":"2023","journal-title":"JCI Insight"},{"key":"2025060410212998600_BCJ-2025-3077C60","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41556-020-0503-2","article-title":"Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis","volume":"22","author":"Park","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"2025060410212998600_BCJ-2025-3077C61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2015.06.002","article-title":"A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC","volume":"28","author":"Mohammad","year":"2015","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C62","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau2922","article-title":"Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition","volume":"12","author":"Augert","year":"2019","journal-title":"Sci. Signal."},{"key":"2025060410212998600_BCJ-2025-3077C63","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood-2017-09-807024","article-title":"LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C\/EBP\u03b1-dependent enhancers in AML","volume":"131","author":"Cusan","year":"2018","journal-title":"Blood"},{"key":"2025060410212998600_BCJ-2025-3077C64","first-page":"2802","article-title":"JAK\/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL","volume":"36","author":"Benyoucef","year":"2022","journal-title":"Leukemia,Nature Publishing Group"},{"key":"2025060410212998600_BCJ-2025-3077C65","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1120911","article-title":"LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials","volume":"14","author":"Noce","year":"2023","journal-title":"Front. Pharmacol."},{"key":"2025060410212998600_BCJ-2025-3077C66","doi-asserted-by":"crossref","unstructured":"Mandl, A., Jasmine, S., Krueger, T., Kumar, R., Coleman, I.M., Dalrymple, S.L.et al. (2024) LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer. bioRxiv2024.01.17.576106https:\/\/doi.org\/10.1101\/2024.01.17.576106","DOI":"10.1101\/2024.01.17.576106"},{"key":"2025060410212998600_BCJ-2025-3077C67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nature04021","article-title":"An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation","volume":"437","author":"Lee","year":"2005","journal-title":"Nature"},{"key":"2025060410212998600_BCJ-2025-3077C68","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.molcel.2005.08.027","article-title":"Regulation of LSD1 histone demethylase activity by its associated factors","volume":"19","author":"Shi","year":"2005","journal-title":"Mol. Cell"},{"key":"2025060410212998600_BCJ-2025-3077C69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccell.2019.06.005","article-title":"Pan-cancer convergence to a small-cell Nneuroendocrine phenotype that shares susceptibilities with hematological malignancies","volume":"36","author":"Balanis","year":"2019","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C70","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-020-00876-8","article-title":"Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets","volume":"12","author":"Krushkal","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"2025060410212998600_BCJ-2025-3077C71","doi-asserted-by":"crossref","first-page":"108296","DOI":"10.1016\/j.celrep.2020.108296","article-title":"SCLC-Cellminer: a resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures","volume":"33","author":"Tlemsani","year":"2020","journal-title":"Cell Rep."},{"key":"2025060410212998600_BCJ-2025-3077C72","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1172\/JCI68760","article-title":"Multicolor microRNA FISH effectively differentiates tumor types","volume":"123","author":"Renwick","year":"2013","journal-title":"J. Clin. Invest."},{"key":"2025060410212998600_BCJ-2025-3077C73","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ajpath.2015.11.020","article-title":"Roles for miR-375 in neuroendocrine differentiation and tumor suppression via notch pathway suppression in merkel cell carcinoma","volume":"186","author":"Abraham","year":"2016","journal-title":"Am. J. Pathol."},{"key":"2025060410212998600_BCJ-2025-3077C74","doi-asserted-by":"crossref","first-page":"113926","DOI":"10.1016\/j.celrep.2024.113926","article-title":"The hippo signaling pathway in development and regeneration","volume":"43","author":"Zhong","year":"2024","journal-title":"Cell Rep."},{"key":"2025060410212998600_BCJ-2025-3077C75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"2025060410212998600_BCJ-2025-3077C76","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ng.2405","article-title":"Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer","volume":"44","author":"Rudin","year":"2012","journal-title":"Nat. Genet."},{"key":"2025060410212998600_BCJ-2025-3077C77","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat. Genet."},{"key":"2025060410212998600_BCJ-2025-3077C78","article-title":"EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer","volume":"121","author":"Yang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2025060410212998600_BCJ-2025-3077C79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/abbs\/gms084","article-title":"Intersection of hippo\/YAP and Wnt\/\u03b2-catenin signaling pathways","volume":"45","author":"Konsavage","year":"2013","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"2025060410212998600_BCJ-2025-3077C80","first-page":"4101","article-title":"YAP\u2011mediated crosstalk between the Wnt and Hippo signaling pathways (Review)","volume":"22","author":"Jiang","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"2025060410212998600_BCJ-2025-3077C81","doi-asserted-by":"crossref","DOI":"10.12703\/P5-17","article-title":"Signal integration in TGF-\u03b2, WNT, and Hippo pathways","volume":"5","author":"Attisano","year":"2013","journal-title":"F1000Prime Rep."},{"key":"2025060410212998600_BCJ-2025-3077C82","doi-asserted-by":"crossref","first-page":"11730","DOI":"10.1074\/jbc.M111.327767","article-title":"Wnt\/\u03b2-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells","volume":"287","author":"Konsavage","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2025060410212998600_BCJ-2025-3077C83","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2022.04.028","article-title":"\u03b2-catenin sustains and is required for YES-associated protein oncogenic activity in cholangiocarcinoma","volume":"163","author":"Zhang","year":"2022","journal-title":"Gastroenterology"},{"key":"2025060410212998600_BCJ-2025-3077C84","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2015.07.013","article-title":"Alternative Wnt signaling activates YAP\/TAZ","volume":"162","author":"Park","year":"2015","journal-title":"Cell"},{"key":"2025060410212998600_BCJ-2025-3077C85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2014.06.013","article-title":"YAP\/TAZ incorporation in the \u03b2-catenin destruction complex orchestrates the Wnt response","volume":"158","author":"Azzolin","year":"2014","journal-title":"Cell"},{"key":"2025060410212998600_BCJ-2025-3077C86","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-017-0244-8","article-title":"YAP triggers the Wnt\/\u03b2-catenin signalling pathway and promotes enterocyte self-renewal, regeneration and tumorigenesis after DSS-induced injury","volume":"9","author":"Deng","year":"2018","journal-title":"Cell Death Dis."},{"key":"2025060410212998600_BCJ-2025-3077C87","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nature15382","article-title":"Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer","volume":"526","author":"Gregorieff","year":"2015","journal-title":"Nature"},{"key":"2025060410212998600_BCJ-2025-3077C88","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/emboj.2011.487","article-title":"A molecular mechanism that links hippo signalling to the inhibition of Wnt\/\u03b2-catenin signalling","volume":"31","author":"Imajo","year":"2012","journal-title":"EMBO J."},{"key":"2025060410212998600_BCJ-2025-3077C89","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1541-7786.MCR-23-0002","article-title":"A comparative study of neuroendocrine heterogeneity in small cell lung cancer and neuroblastoma","volume":"21","author":"Cai","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C90","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tibs.2022.12.005","article-title":"Therapeutic targeting of TEAD transcription factors in cancer","volume":"48","author":"Pobbati","year":"2023","journal-title":"Trends Biochem. Sci."},{"key":"2025060410212998600_BCJ-2025-3077C91","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nchembio.2036","article-title":"Autopalmitoylation of TEAD proteins regulates transcriptional output of the hippo pathway","volume":"12","author":"Chan","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"2025060410212998600_BCJ-2025-3077C92","first-page":"4399","article-title":"The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma","volume":"10","author":"Kaneda","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C93","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","article-title":"Small molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"2025060410212998600_BCJ-2025-3077C94","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers","volume":"5","author":"Chapeau","year":"2024","journal-title":"Nat. Cancer"},{"key":"2025060410212998600_BCJ-2025-3077C95","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT006","article-title":"Abstract CT006: first-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)\/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations","volume":"83","author":"Yap","year":"2023","journal-title":"Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C96","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/2159-8290.CD-23-1529","article-title":"MARK2\/MARK3 kinases are catalytic codependencies of YAP\/TAZ in human cancer","volume":"14","author":"Klingbeil","year":"2024","journal-title":"Cancer Discov."},{"key":"2025060410212998600_BCJ-2025-3077C97","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"2025060410212998600_BCJ-2025-3077C98","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"2025060410212998600_BCJ-2025-3077C99","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","article-title":"A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion","volume":"21","author":"Dersh","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"2025060410212998600_BCJ-2025-3077C100","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"2025060410212998600_BCJ-2025-3077C101","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol. Cancer"},{"key":"2025060410212998600_BCJ-2025-3077C102","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"2025060410212998600_BCJ-2025-3077C103","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","article-title":"Immunogenomic landscape of neuroendocrine prostate cancer","volume":"29","author":"Bhinder","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C104","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-14-0005","article-title":"Downregulation of MHC-I expression is prevalent but reversible in merkel cell carcinoma","volume":"2","author":"Paulson","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"2025060410212998600_BCJ-2025-3077C105","doi-asserted-by":"crossref","first-page":"102606","DOI":"10.1016\/j.ctrv.2023.102606","article-title":"Shaping the tumor immune microenvironment of SCLC: mechanisms, and opportunities for immunotherapy","volume":"120","author":"Chen","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"2025060410212998600_BCJ-2025-3077C106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007798","article-title":"Neuroblastoma: an ongoing cold front for cancer immunotherapy","volume":"11","author":"Kennedy","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"2025060410212998600_BCJ-2025-3077C107","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"2025060410212998600_BCJ-2025-3077C108","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2025060410212998600_BCJ-2025-3077C109","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"2025060410212998600_BCJ-2025-3077C110","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C111","doi-asserted-by":"crossref","first-page":"115","DOI":"10.21147\/j.issn.1000-9604.2020.01.13","article-title":"Advances and challenges in immunotherapy of small cell lung cancer","volume":"32","author":"Guo","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C112","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C113","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","article-title":"Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade","volume":"42","author":"Nabet","year":"2024","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C114","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jtho.2020.11.006","article-title":"YAP1 expression in SCLC defines a distinct subtype with T-cell-inflamed phenotype","volume":"16","author":"Owonikoko","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-06053-y","article-title":"YAP1 expression is associated with survival and immunosuppression in small cell lung cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Cell Death Dis."},{"key":"2025060410212998600_BCJ-2025-3077C116","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: A comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C117","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-23-2360","article-title":"Molecular and pathologic characterization of yap1-expressing small cell lung cancer cell lines leads to reclassification as smarca4-deficient malignancies","volume":"30","author":"Ng","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C118","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-22-1128","article-title":"Inhibition of lsd1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and t-cell killing","volume":"28","author":"Hiatt","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C119","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jtho.2022.05.014","article-title":"Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen presentation and overcomes programmed death-ligand 1 blockade resistance in SCLC","volume":"17","author":"Nguyen","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the mhc class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C121","doi-asserted-by":"crossref","first-page":"TPS8130","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8130","article-title":"Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer","volume":"42","author":"Desai","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C122","first-page":"e20606","article-title":"Phase I study of entinostat (Ent), atezolizumab (A), carboplatin (C), and etoposide (E) in previously untreated extensive-stage small cell lung cancer (ES-SCLC), ETCTN 10399","volume":"40","author":"Gentzler","year":"2022","journal-title":"JCO, Wolters Kluwer"},{"key":"2025060410212998600_BCJ-2025-3077C123","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041106","article-title":"Immunotherapy in melanoma: recent advances and future directions","volume":"15","author":"Knight","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025060410212998600_BCJ-2025-3077C124","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.3390\/curroncol31060258","article-title":"A review of immunotherapy in non-small-cell lung cancer","volume":"31","author":"Capella","year":"2024","journal-title":"Curr. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C126","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06300-3","article-title":"Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA","volume":"9","author":"Paulson","year":"2018","journal-title":"Nat. Commun."},{"key":"2025060410212998600_BCJ-2025-3077C127","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-017-0421-3","article-title":"Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways","volume":"10","author":"Huang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent MDSC infiltration impairs tumor progression","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discov."},{"key":"2025060410212998600_BCJ-2025-3077C129","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/2159-8290.CD-17-1124","article-title":"YAP Is essential for treg-mediated suppression of antitumor immunity","volume":"8","author":"Ni","year":"2018","journal-title":"Cancer Discov."},{"key":"2025060410212998600_BCJ-2025-3077C130","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1159\/000464380","article-title":"YAP-1 promotes tregs differentiation in hepatocellular carcinoma by enhancing TGFBR2 transcription","volume":"41","author":"Fan","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"2025060410212998600_BCJ-2025-3077C131","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/0008-5472.CAN-17-3139","article-title":"The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1C","volume":"78","author":"Janse van Rensburg","year":"2018","journal-title":"Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C132","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","article-title":"YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma","volume":"6","author":"Kim","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"2025060410212998600_BCJ-2025-3077C133","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bbrc.2017.07.007","article-title":"Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma","volume":"491","author":"Lee","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2025060410212998600_BCJ-2025-3077C134","doi-asserted-by":"crossref","first-page":"114576","DOI":"10.18632\/oncotarget.23051","article-title":"YAP regulates PD-L1 expression in human NSCLC cells","volume":"8","author":"Miao","year":"2017","journal-title":"Oncotarget"},{"key":"2025060410212998600_BCJ-2025-3077C135","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nri3339","article-title":"NLRC5: a key regulator of MHC class I-dependent immune responses","volume":"12","author":"Kobayashi","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"2025060410212998600_BCJ-2025-3077C136","doi-asserted-by":"crossref","first-page":"114003","DOI":"10.1016\/j.celrep.2024.114003","article-title":"Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity","volume":"43","author":"Peng","year":"2024","journal-title":"Cell Rep."},{"key":"2025060410212998600_BCJ-2025-3077C137","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"2025060410212998600_BCJ-2025-3077C138","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"2025060410212998600_BCJ-2025-3077C139","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C140","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1158\/2326-6066.CIR-22-0227","article-title":"Hippo signaling pathway regulates cancer cell-intrinsic MHC-II expression","volume":"10","author":"Zeng","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"2025060410212998600_BCJ-2025-3077C141","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"2025060410212998600_BCJ-2025-3077C142","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030593","article-title":"Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies","volume":"9","author":"Puca","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2025060410212998600_BCJ-2025-3077C143","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00060","article-title":"The many faces of neuroendocrine differentiation in prostate cancer progression","volume":"4","author":"Terry","year":"2014","journal-title":"Front. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C144","article-title":"Neuroendocrine transformation as a mechanism of resistance to targeted lung cancer therapies: emerging mechanisms and their therapeutic implications","volume":"17","author":"Joshi","year":"2025","journal-title":"Cancers, Multidisciplinary Digital Publishing Institute"},{"key":"2025060410212998600_BCJ-2025-3077C145","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16162-3","article-title":"Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers","volume":"11","author":"Sfakianos","year":"2020","journal-title":"Nat. Commun."},{"key":"2025060410212998600_BCJ-2025-3077C146","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101201","article-title":"Urothelial-to-neural plasticity drives progression to small cell bladder cancer","volume":"23","author":"Yang","year":"2020","journal-title":"iScience"},{"key":"2025060410212998600_BCJ-2025-3077C147","first-page":"4045","article-title":"Conversion to neuroendocrine carcinoma from squamous cell carcinoma of the esophagus after definitive chemoradiotherapy","volume":"36","author":"Morita","year":"2016","journal-title":"Anticancer Research, International Institute of Anticancer Research"},{"key":"2025060410212998600_BCJ-2025-3077C148","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C149","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C150","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C151","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1158\/1538-7445.AM2022-5364","article-title":"Abstract 5364: The TEAD autopalmitoylation inhibitor VT3989 improves efficacy and increases durability of efficacy of osimertinib in preclinical EGFR mutant tumor models","volume":"82","author":"Tang","year":"2022","journal-title":"Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C152","article-title":"Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas","volume":"8","author":"Lee","year":"2018","journal-title":"Sci. Rep."},{"key":"2025060410212998600_BCJ-2025-3077C153","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C154","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/0003-4819-88-6-805","article-title":"Mixed anaplastic small-cell and squamous-cell carcinoma of the lung","volume":"88","author":"Brereton","year":"1978","journal-title":"Ann. Intern. Med."},{"key":"2025060410212998600_BCJ-2025-3077C155","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/0002-9343(79)91113-6","article-title":"Changes in morphologic and biochemical characteristics of small cell carcinoma of the lung. a clinicopathologic study","volume":"66","author":"Abeloff","year":"1979","journal-title":"Am. J. Med."},{"key":"2025060410212998600_BCJ-2025-3077C156","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","article-title":"MYC drives tetmporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate","volume":"38","author":"Ireland","year":"2020","journal-title":"Cancer Cell"},{"key":"2025060410212998600_BCJ-2025-3077C157","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1759-7714.12297","article-title":"Notch1 controls cell chemoresistance in small cell lung carcinoma cells","volume":"7","author":"Hassan","year":"2016","journal-title":"Thorac. Cancer"},{"key":"2025060410212998600_BCJ-2025-3077C158","first-page":"2594","article-title":"Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin","volume":"47","author":"Mirski","year":"1987","journal-title":"Cancer Res."},{"key":"2025060410212998600_BCJ-2025-3077C159","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s13577-022-00669-6","article-title":"The role of YAP1 in small cell lung cancer","volume":"35","author":"Saito","year":"2022","journal-title":"Hum. Cell"},{"key":"2025060410212998600_BCJ-2025-3077C160","article-title":"Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer","volume":"10","author":"Inoue","year":"2021","journal-title":"ELife Sciences Publications, Ltd"},{"key":"2025060410212998600_BCJ-2025-3077C161","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1172\/JCI114630","article-title":"v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line","volume":"85","author":"Falco","year":"1990","journal-title":"J. Clin. Invest."},{"key":"2025060410212998600_BCJ-2025-3077C162","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1073\/pnas.85.17.6523","article-title":"v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer","volume":"85","author":"Mabry","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2025060410212998600_BCJ-2025-3077C163","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1038\/sj.onc.1201845","article-title":"Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins","volume":"16","author":"Risse-Hackl","year":"1998","journal-title":"Oncogene"},{"key":"2025060410212998600_BCJ-2025-3077C164","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164611","article-title":"Deciphering the enigma of neuroendocrine prostate cancer","volume":"132","author":"Karzai","year":"2022","journal-title":"J. Clin. Invest."},{"key":"2025060410212998600_BCJ-2025-3077C165","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature22323","article-title":"Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer","volume":"545","author":"Lim","year":"2017","journal-title":"Nature"},{"key":"2025060410212998600_BCJ-2025-3077C166","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"2025060410212998600_BCJ-2025-3077C167","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/doi\/10.1042\/BCJ20253077\/973652\/bcj-2025-3077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/doi\/10.1042\/BCJ20253077\/973652\/bcj-2025-3077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:22:08Z","timestamp":1749046928000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/482\/11\/741\/236125\/Molecular-basis-and-therapeutic-implications-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":167,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20253077","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,28]]}}}